Evidence map›Paper›PMID 38379722›Full record

ArticleMethodsX2024

Conducting nationwide cohort COVID-19 serology surveys on a nation with limited resources and decentralized governance: Evidence from Indonesia.

Muhammad Noor Farid, Hafizah Jusril, Pandu Riono, Wiji Wahyuningsih, Elmarizha Sekar Utami, Wirabrata, Iwan Ariawan

Abstract read
In one paragraph

Article in MethodsX, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad Noor FaridDepartment of Biostatistics and Population Studies, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Hafizah JusrilDepartment of Biostatistics and Population Studies, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Pandu RionoDepartment of Biostatistics and Population Studies, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Wiji WahyuningsihDepartment of Biostatistics and Population Studies, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Elmarizha Sekar UtamiDepartment of Biostatistics and Population Studies, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
WirabrataCentre for Health Resilience and Resource Policy, Ministry of Health, Jakarta, Indonesia.
Iwan AriawanDepartment of Biostatistics and Population Studies, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowing the level of SARS-CoV-2 transmission is crucial for decision-making on Coronavirus disease (COVID-19) handling. Guidelines for measuring SARS-CoV-2 antibodies to estimate seroprevalence are conceptually straightforward and internationally available. However, challenges exist for developing countries with limited laboratory capacity, diverse geographical topography, fragmented health information systems and limited resources such as Indonesia. One year after the first case was confirmed in Indonesia, approximately ten infections were undiagnosed or underreported for every reported case. Under those circumstances, we described the method and lessons learned in conducting nationwide cohort COVID-19 serology surveys in a nation with limited resources, such as Indonesia. •Strong cross-sectoral collaboration between ministries and levels of governance (central and subnational) enables strategic use of civil registration database for efficient sampling.•All agglomeration districts (highly dense population and urban area) were selected as study sites, and additional non-agglomeration districts were selected using probability-proportional-to-size (PPS).•Involving the experienced phlebotomist in community health service provider and district laboratory cut down preparation time.

Indexed as

AntibodyCOVID-19ImmunologyPopulation-based, age and sex-stratified prospective panel study for COVID-19SARS-CoV-2SeroepidemiologySeroprevalenceVaccination

Identifiers

PMID38379722
PMCPMC10877936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.